NFX Nuformix Plc

14 February 2025

Nuformix plc

("Nuformix" or the "Company")

Posting of Annual Report and Notice of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2024 (the "Annual Financial Report 2024") and the 2025 Notice of Annual General Meeting ("AGM") are today being posted to its shareholders.

A full pdf version of the Annual Financial Report 2024 together with the Notice of AGM will shortly be available for download from the Company's website at: https://nuformix.com/document-center/

The AGM will be held on 20 March 2025 at 10.00 a.m. at the offices of Shakespeare Martineau, 6^th floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.